ProQR Therapeutics NV
PRQR
View Detailed Chart
2.045USD
-0.165-7.47%
Market hours （ET）Quotes delayed by 15 min
220.27MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-7.47%
5 Days
-24.82%
1 Month
-13.35%
6 Months
+31.09%
Year to Date
-22.83%
1 Year
-43.82%
View Detailed Chart
TradingKey Stock Score of ProQR Therapeutics NV
Currency: USD Updated: 2025-11-06Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ProQR Therapeutics NV's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
8.375
Target Price
+251.89%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ProQR Therapeutics NV Highlights
StrengthsRisks
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 348.01% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 18.01M.
Fairly Valued
The company’s latest PE is -6.40, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 41.23M shares, decreasing 10.50% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 750.00K shares of this stock.
ProQR Therapeutics NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
ProQR Therapeutics NV Info
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Ticker SymbolPRQR
CompanyProQR Therapeutics NV
CEOMr. Daniel Anton de Boer
Websitehttps://www.proqr.com/
Related Instruments
-2.76%
-0.32%
-0.57%
+1.40%
-0.14%
-0.20%
+0.51%
-2.40%
-3.56%
-0.02%
-0.14%
-0.32%
-1.71%
-0.30%
-1.13%
+0.80%
0.00%
-0.46%
-1.25%
-1.19%Popular Symbols
